Goldman Sachs Group Inc Kymera Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 344,237 shares of KYMR stock, worth $15.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

344,237

Previous 344,237 -0.0%

Holding current value

$15.8 Million

Previous $9.42 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$27.37 - $44.36 $2.46 Million - $3.98 Million	-89,707 Reduced 20.67%	344,237 $9.42 Million
Q4 2024 Feb 11, 2025	BUY	$39.06 - $51.84 $8.17 Million - $10.8 Million	209,113 Added 93.01%	433,944 $17.5 Million
Q3 2024 Nov 14, 2024	SELL	$30.16 - $52.4 $7.16 Million - $12.4 Million	-237,478 Reduced 51.37%	224,831 $10.6 Million
Q2 2024 Aug 13, 2024	BUY	$29.85 - $39.42 $351,961 - $464,801	11,791 Added 2.62%	462,309 $13.8 Million
Q1 2024 May 15, 2024	SELL	$22.9 - $43.57 $5.13 Million - $9.77 Million	-224,137 Reduced 33.22%	450,518 $18.1 Million
Q4 2023 Feb 13, 2024	BUY	$10.97 - $26.84 $5.16 Million - $12.6 Million	469,947 Added 229.57%	674,655 $17.2 Million
Q3 2023 May 14, 2024	SELL	$13.9 - $23.88 $6.53 Million - $11.2 Million	-469,947 Reduced 69.66%	204,708 $2.85 Million
Q3 2023 Nov 14, 2023	SELL	$13.9 - $23.88 $1.9 Million - $3.27 Million	-136,837 Reduced 40.06%	204,708 $2.85 Million
Q2 2023 May 14, 2024	BUY	$22.4 - $34.92 $1 Million - $1.56 Million	44,702 Added 15.06%	341,545 $7.85 Million
Q2 2023 Aug 14, 2023	BUY	$22.4 - $34.92 $1 Million - $1.56 Million	44,702 Added 15.06%	341,545 $7.85 Million
Q1 2023 May 14, 2024	SELL	$24.84 - $38.75 $1.02 Million - $1.59 Million	-41,087 Reduced 12.16%	296,843 $8.8 Million
Q1 2023 May 11, 2023	SELL	$24.84 - $38.75 $1.02 Million - $1.59 Million	-41,087 Reduced 12.16%	296,843 $8.8 Million
Q4 2022 May 14, 2024	BUY	$19.57 - $30.92 $22,916 - $36,207	1,171 Added 0.35%	337,930 $8.43 Million
Q4 2022 Feb 13, 2023	BUY	$19.57 - $30.92 $22,916 - $36,207	1,171 Added 0.35%	337,930 $8.43 Million
Q3 2022 May 14, 2024	BUY	$20.91 - $34.27 $1.24 Million - $2.04 Million	59,495 Added 21.46%	336,759 $7.33 Million
Q3 2022 Nov 10, 2022	BUY	$20.91 - $34.27 $1.24 Million - $2.04 Million	59,495 Added 21.46%	336,759 $7.33 Million
Q2 2022 May 14, 2024	SELL	$14.13 - $42.55 $5.62 Million - $16.9 Million	-397,391 Reduced 58.9%	277,264 $5.46 Million
Q2 2022 Aug 15, 2022	BUY	$14.13 - $42.55 $471,065 - $1.42 Million	33,338 Added 13.67%	277,264 $5.46 Million
Q1 2022 May 16, 2022	SELL	$35.3 - $64.68 $842,399 - $1.54 Million	-23,864 Reduced 8.91%	243,926 $10.3 Million
Q4 2021 Feb 14, 2022	BUY	$49.91 - $65.56 $4.37 Million - $5.74 Million	87,583 Added 48.6%	267,790 $17 Million
Q3 2021 Nov 10, 2021	BUY	$47.8 - $66.66 $8.61 Million - $12 Million	180,207 New	180,207 $10.6 Million

Others Institutions Holding KYMR

# of Institutions

181

Shares Held

67.4M

Call Options Held

223K

Put Options Held

241K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.51B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Kymera Therapeutics, Inc. Transaction History